Patents Assigned to H. Lundbeck
  • 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
    Patent number: 11491140
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: November 8, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Imidazopyrazinones as PDE1 inhibitors
    Patent number: 11472810
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: October 18, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • Modulators of the NMDA receptor
    Patent number: 11466027
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • 5-HT6 receptor antagonists for use in the treatment of alzheimer's disease in patient subpopulation carrying APOE4 alleles
    Patent number: 11464759
    Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventor: Kristian Windfeld
  • 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
    Patent number: 11458134
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 4, 2022
    Assignee: H. Lundbeck A/S
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm, Michael J. Mealy
  • Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
    Patent number: 11447560
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: September 20, 2022
    Assignees: KECK GRADUATE INSTITUTE, H. LUNDBECK A/S
    Inventors: James M. Cregg, John A. Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstrorukov
  • yeast cultures comprising reduced antibody-associated variants
    Patent number: 11447540
    Abstract: Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 20, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: Gary Lesnicki, Patricia Dianne McNeill, Franz Hartner, Mark Young
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES
    Publication number: 20220280455
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Anette Graven Sams, Mario Rottlãnder, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Jesper Frank Bastlund, Jelena Ivkovic, Karina Krøjer Søby, Morten Grupe Larsen
  • MAGL inhibitors
    Patent number: 11434222
    Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: September 6, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: John J. M. Wiener, Cheryl A. Grice, Daniel J. Buzard, Justin S. Cisar, Olivia Delene Weber, Amy Allan, Nicholas Raffaele, Jeanne Moody, Michael B. Shaghafi
  • Alcohol derivatives as KV7 potassium channel openers
    Patent number: 11434199
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: September 6, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • Anti-ACTH antibodies and use thereof
    Patent number: 11427631
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: August 30, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11421024
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: August 23, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220257623
    Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: July 28, 2021
    Publication date: August 18, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
  • NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220220077
    Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 14, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Morten Jørgensen, Erhad Ascic, Martin Juhl, Klaus Gjervig Jensen, Ask Püschl, Benny Bang-Andersen
  • NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES
    Publication number: 20220213136
    Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Morten Jørgensen, Martin Juhl, Klaus Gjervig Jensen
  • CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220213040
    Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Morten Jørgensen, Erhad Ascic, Karin Sjödin, Klaus Gjervig Jensen, Jarkko Tapani Rautio
  • NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220213071
    Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Morten Jørgensen, Martin Juhl, Klaus Gjervig Jensen, Lisbet Kvænø
  • PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20220213117
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: January 25, 2022
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID
    Publication number: 20220194978
    Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.
    Type: Application
    Filed: August 2, 2021
    Publication date: June 23, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Martin Juhl, Frans Dennis Therkelsen, Tobias Gylling Frihed
  • PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID
    Publication number: 20220185839
    Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to a new intermediate of said process.
    Type: Application
    Filed: July 26, 2021
    Publication date: June 16, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Martin Juhl, Lisbet Kværnø, Mikkel Fog Jacobsen